EA201891333A1 - Фактор viii с увеличенным периодом полужизни и уменьшенными способностями по связыванию лигандов - Google Patents

Фактор viii с увеличенным периодом полужизни и уменьшенными способностями по связыванию лигандов

Info

Publication number
EA201891333A1
EA201891333A1 EA201891333A EA201891333A EA201891333A1 EA 201891333 A1 EA201891333 A1 EA 201891333A1 EA 201891333 A EA201891333 A EA 201891333A EA 201891333 A EA201891333 A EA 201891333A EA 201891333 A1 EA201891333 A1 EA 201891333A1
Authority
EA
Eurasian Patent Office
Prior art keywords
factor viii
ligands
principle
connect
reduced ability
Prior art date
Application number
EA201891333A
Other languages
English (en)
Inventor
Петер Турецек
Геральд Шренк
Юрген Зикманн
Original Assignee
Баксалта Инкорпорейтед
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баксалта Инкорпорейтед, Баксалта Гмбх filed Critical Баксалта Инкорпорейтед
Publication of EA201891333A1 publication Critical patent/EA201891333A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к материалам и способам конъюгирования водорастворимого полимера с окисленным углеводным остатком терапевтического белка, включающим контактирование окисленного углеводного остатка с активированным водорастворимым полимером в условиях, которые обеспечивают конъюгацию. Более конкретно, данное изобретение относится к модифицированному рекомбинантному фактору VIII (FVIII) с увеличенным периодом полужизни и уменьшенными способностями по связыванию лигандов.
EA201891333A 2015-12-03 2016-12-05 Фактор viii с увеличенным периодом полужизни и уменьшенными способностями по связыванию лигандов EA201891333A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262674P 2015-12-03 2015-12-03
PCT/US2016/064979 WO2017096383A1 (en) 2015-12-03 2016-12-05 Factor viii with extended half-life and reduced ligand-binding properties

Publications (1)

Publication Number Publication Date
EA201891333A1 true EA201891333A1 (ru) 2018-12-28

Family

ID=57614469

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891333A EA201891333A1 (ru) 2015-12-03 2016-12-05 Фактор viii с увеличенным периодом полужизни и уменьшенными способностями по связыванию лигандов

Country Status (16)

Country Link
US (2) US20170349644A1 (ru)
EP (1) EP3383895A1 (ru)
JP (1) JP2019510022A (ru)
KR (1) KR20180088727A (ru)
CN (1) CN108884146A (ru)
AR (1) AR106914A1 (ru)
AU (1) AU2016362606A1 (ru)
BR (1) BR112018011259A2 (ru)
CA (1) CA3007364A1 (ru)
EA (1) EA201891333A1 (ru)
IL (1) IL259760A (ru)
MX (1) MX2018006738A (ru)
PH (1) PH12018501174A1 (ru)
SG (2) SG10202004031WA (ru)
TW (1) TW201731869A (ru)
WO (1) WO2017096383A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2016362606A1 (en) * 2015-12-03 2018-06-28 Takeda Pharmaceutical Company Limited Factor VIII with extended half-life and reduced ligand-binding properties

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
EP1129186B2 (de) 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
ATE313554T1 (de) 2000-05-16 2006-01-15 Lipoxen Technologies Ltd Derivatisierung von proteinen in wässrigem lösungsmittel
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
EP1653991A2 (en) 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
RU2333223C2 (ru) 2003-08-12 2008-09-10 Лайпоксен Текнолоджиз Лимитед Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе
ES2381110T3 (es) * 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1694274B1 (en) 2003-12-03 2013-04-24 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
WO2006016168A2 (en) 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
CN103497247A (zh) * 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2595442C2 (ru) * 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
JP5813641B2 (ja) * 2009-08-24 2015-11-17 アムニクス オペレーティング インコーポレイテッド 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
EP2598172B1 (en) * 2010-07-30 2019-03-27 Baxalta GmbH Nucleophilic catalysts for oxime linkage
JP2015521589A (ja) * 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
AU2016362606A1 (en) * 2015-12-03 2018-06-28 Takeda Pharmaceutical Company Limited Factor VIII with extended half-life and reduced ligand-binding properties

Also Published As

Publication number Publication date
CA3007364A1 (en) 2017-06-08
US20170349644A1 (en) 2017-12-07
IL259760A (en) 2018-07-31
JP2019510022A (ja) 2019-04-11
AR106914A1 (es) 2018-02-28
EP3383895A1 (en) 2018-10-10
KR20180088727A (ko) 2018-08-06
PH12018501174A1 (en) 2019-01-21
US20190240295A1 (en) 2019-08-08
CN108884146A (zh) 2018-11-23
WO2017096383A1 (en) 2017-06-08
TW201731869A (zh) 2017-09-16
SG10202004031WA (en) 2020-05-28
BR112018011259A2 (pt) 2018-11-21
MX2018006738A (es) 2018-09-21
AU2016362606A1 (en) 2018-06-28
SG11201804666QA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CY1122494T1 (el) Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
CY1123385T1 (el) Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12017500892A1 (en) Antigen binding molecules comprising a tnf family ligand trimer
CY1121891T1 (el) Τροποποιημενα με γενετικη μηχανικη πολυπεπτιδια της λυασης φαινυλαλανινης-αμμωνιας
PH12018502367A1 (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
MX2022002504A (es) Anticuerpos para cd40.
EA201790371A1 (ru) Модифицированные варианты il-2, которые селективно активируют регуляторные т-клетки, для лечения аутоиммунных заболеваний
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
NZ731185A (en) Bicyclic peptide ligands specific for mt1-mmp
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
MX2018008310A (es) Proteinas de fusion de union a ox40 multivalentes y multiespecificas.
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201390940A1 (ru) Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком
NZ730763A (en) Methods of treating a tauopathy
MD3665192T2 (ro) Polipeptide de legare a receptorului de transferrină modificate genetic
EA201891573A1 (ru) Конъюгат терапевтических ферментов
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
EA201691374A1 (ru) Инсулин длительного действия и его применение